|
Pfizer’s Inlyta Falls Flat as First-Line Treatment in Kidney Cancer Trial
Pfizer’s advanced kidney cancer drug Inlyta missed its primary endpoint in a late-stage trial of treatment-naïve patients, leaving the company’s hopes for a first-line indication in doubt.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives